Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.

Hueber, Wolfgang

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. [electronic resource] - Gut Dec 2012 - 1693-700 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1468-3288

10.1136/gutjnl-2011-301668 doi


Adolescent
Adult
Aged
Anti-Inflammatory Agents--therapeutic use
Antibodies, Monoclonal--therapeutic use
Antibodies, Monoclonal, Humanized
Bayes Theorem
Biomarkers--metabolism
Crohn Disease--drug therapy
Double-Blind Method
Drug Administration Schedule
Female
Genetic Markers
Humans
Infusions, Intravenous
Interleukin-17--antagonists & inhibitors
Leukocyte L1 Antigen Complex--metabolism
Male
Middle Aged
Polymorphism, Single Nucleotide
Severity of Illness Index
Treatment Failure
Young Adult